datacentre@scilifelab.se
) if you think anything looks out of place.Jernbom AF, Skoglund L, Pin E, Sjöberg R, Tegel H, Hober S, Rostami E, Rasmusson A, Cunningham JL, Havervall S, Thålin C, Månberg A, Nilsson P
Nat Commun 15 (1) 8941 [2024-10-17; online 2024-10-17]
Autoantibodies have been shown to be implied in COVID-19 but the emerging autoantibody repertoire remains largely unexplored. We investigated the new-onset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients at five time points over a 16-month period in 2020 and 2021 using proteome-wide and targeted protein and peptide arrays. Our results show that prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months. We found an increased prevalence of new-onset autoantibodies after severe COVID-19 and demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19. Using epitope mapping, we determined the main epitopes of selected new-onset autoantibodies, validated them in independent cohorts of neuro-COVID and pre-pandemic healthy controls, and identified sequence similarities suggestive of molecular mimicry between main epitopes and the conserved fusion peptide of the SARS-CoV-2 Spike glycoprotein. Our work describes the complexity and dynamics of the autoantibody repertoire emerging with COVID-19 and supports the need for continued analysis of the new-onset autoantibody repertoire to elucidate the mechanisms of the post-COVID-19 condition.
Autoimmunity and Serology Profiling [Collaborative]
PubMed 39414823
DOI 10.1038/s41467-024-53356-5
Crossref 10.1038/s41467-024-53356-5
pmc: PMC11484904
pii: 10.1038/s41467-024-53356-5